FDA Approves Aflibercept (Eylea) Biosimilars, Yesafili and Opuviz

Drug Topics May 21, 2024
Lauren Biscaldi, MS, Managing Editor

These aflibercept biosimilars are used to treat wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.

Earlier this week, the FDA approved aflibercept-jbvf (Yesafili) and aflibercept-yszy (Opuviz), the first interchangeable biosimilars for aflibercept (Eyela).^1,2 These medications are used to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Both medications are vascular endothelial growth factor (VEGF) inhibitors, administered intravitreally as a 2 mg injectable solution. Anti-VEGF medications stop abnormal blood vessels from leaking, growing, and bleeding under the retina, which leads to pain and vision loss for patients.

More than 19 million Americans are living with age-related macular degeneration. The approval of these medications offers an additional treatment option to this...

Today's Sponsors

Today's Sponsor